心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2021更新 NICE指南：急性心力衰竭的诊断和管理

2021-11-17 英国国家卫生与临床优化研究所 NICE官网

心力衰竭

该指南涵盖了 18 岁及以上人群的急性心力衰竭或可能的急性心力衰竭的诊断和管理。它旨在改善因心力衰竭而严重不适的人的即时护理。

中文标题：

2021更新 NICE指南：急性心力衰竭的诊断和管理

英文标题：

Acute heart failure: diagnosis and management

发布机构：

英国国家卫生与临床优化研究所

发布日期：

2021-11-17

简要介绍：

该指南涵盖了 18 岁及以上人群的急性心力衰竭或可能的急性心力衰竭的诊断和管理。它旨在改善因心力衰竭而严重不适的人的即时护理。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021更新 NICE指南：急性心力衰竭：诊断和管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=8d93e1c002265981, title=2021更新 NICE指南：急性心力衰竭的诊断和管理, enTitle=Acute heart failure: diagnosis and management, guiderFrom=NICE官网, authorId=0, author=, summary=该指南涵盖了 18 岁及以上人群的急性心力衰竭或可能的急性心力衰竭的诊断和管理。它旨在改善因心力衰竭而严重不适的人的即时护理。, cover=https://img.medsci.cn/20211118/1637243901615_1608702.png, journalId=0, articlesId=null, associationId=85, associationName=英国国家卫生与临床优化研究所, associationIntro=英国国家卫生与临床优化研究所（NICE，National Institute for Health and Clinical Excellence）是NHS的组织，设在伦敦和曼彻斯特。NICE成立于1999年4月1日，目标是确保每个英格兰和威尔士人平等享有NHS医疗的机会。NICE制定指南，设定质量标准，管理国家数据库，为NHS、当地权威部门和其他组织提供指南。, copyright=0, guiderPublishedTime=Wed Nov 17 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #0e0e0e;">该指南涵盖了 18 岁及以上人群的急性心力衰竭或可能的急性心力衰竭的诊断和管理。</span><span style="color: #0e0e0e;">它旨在改善因心力衰竭而严重不适的人的即时护理。</span></p>, tagList=[TagDto(tagId=335, tagName=心力衰竭)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=335, guiderKeyword=心力衰竭, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3643, appHits=503, showAppHits=0, pcHits=1541, showPcHits=3130, likes=1, shares=43, comments=13, approvalStatus=1, publishedTime=Thu Nov 18 22:04:03 CST 2021, publishedTimeString=2021-11-17, pcVisible=1, appVisible=1, editorId=5589422, editor=admintest, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=5, createdBy=null, createdName=dajiong, createdTime=Thu Nov 18 22:03:00 CST 2021, updatedBy=5589422, updatedName=admintest, updatedTime=Fri Jan 05 12:58:40 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021更新 NICE指南：急性心力衰竭：诊断和管理.pdf)])
2021更新 NICE指南：急性心力衰竭：诊断和管理.pdf
下载请点击：
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2116967, encodeId=9150211696e5f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc408549151, createdName=ms8000001725758454, createdTime=Tue Feb 28 23:19:15 CST 2023, time=2023-02-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1222848, encodeId=313d1222848f9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fab96394669, createdName=ms3000000753612435, createdTime=Fri May 27 18:48:56 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222055, encodeId=28da122205541, content=回复能给积分？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220525/80a0ef79551841cbae693eaac50470ac/d51eaf2146ea41808ad01ccd5457204a.jpg, createdBy=c9596160557, createdName=ms6000001274998563, createdTime=Tue May 24 12:19:44 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221921, encodeId=e5d61221921f5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f2d8154831, createdName=ms3000000261038156, createdTime=Tue May 24 09:19:16 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198424, encodeId=ab521198424e3, content=攒积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=371e2458071, createdName=1240f287m62暂无昵称, createdTime=Tue Mar 01 17:41:32 CST 2022, time=2022-03-01, status=1, ipAttribution=)]
    2023-02-28 ms8000001725758454 来自广东省

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2116967, encodeId=9150211696e5f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc408549151, createdName=ms8000001725758454, createdTime=Tue Feb 28 23:19:15 CST 2023, time=2023-02-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1222848, encodeId=313d1222848f9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fab96394669, createdName=ms3000000753612435, createdTime=Fri May 27 18:48:56 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222055, encodeId=28da122205541, content=回复能给积分？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220525/80a0ef79551841cbae693eaac50470ac/d51eaf2146ea41808ad01ccd5457204a.jpg, createdBy=c9596160557, createdName=ms6000001274998563, createdTime=Tue May 24 12:19:44 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221921, encodeId=e5d61221921f5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f2d8154831, createdName=ms3000000261038156, createdTime=Tue May 24 09:19:16 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198424, encodeId=ab521198424e3, content=攒积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=371e2458071, createdName=1240f287m62暂无昵称, createdTime=Tue Mar 01 17:41:32 CST 2022, time=2022-03-01, status=1, ipAttribution=)]
    2022-05-27 ms3000000753612435

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2116967, encodeId=9150211696e5f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc408549151, createdName=ms8000001725758454, createdTime=Tue Feb 28 23:19:15 CST 2023, time=2023-02-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1222848, encodeId=313d1222848f9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fab96394669, createdName=ms3000000753612435, createdTime=Fri May 27 18:48:56 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222055, encodeId=28da122205541, content=回复能给积分？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220525/80a0ef79551841cbae693eaac50470ac/d51eaf2146ea41808ad01ccd5457204a.jpg, createdBy=c9596160557, createdName=ms6000001274998563, createdTime=Tue May 24 12:19:44 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221921, encodeId=e5d61221921f5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f2d8154831, createdName=ms3000000261038156, createdTime=Tue May 24 09:19:16 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198424, encodeId=ab521198424e3, content=攒积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=371e2458071, createdName=1240f287m62暂无昵称, createdTime=Tue Mar 01 17:41:32 CST 2022, time=2022-03-01, status=1, ipAttribution=)]
    2022-05-24 ms6000001274998563

    回复能给积分？

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2116967, encodeId=9150211696e5f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc408549151, createdName=ms8000001725758454, createdTime=Tue Feb 28 23:19:15 CST 2023, time=2023-02-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1222848, encodeId=313d1222848f9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fab96394669, createdName=ms3000000753612435, createdTime=Fri May 27 18:48:56 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222055, encodeId=28da122205541, content=回复能给积分？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220525/80a0ef79551841cbae693eaac50470ac/d51eaf2146ea41808ad01ccd5457204a.jpg, createdBy=c9596160557, createdName=ms6000001274998563, createdTime=Tue May 24 12:19:44 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221921, encodeId=e5d61221921f5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f2d8154831, createdName=ms3000000261038156, createdTime=Tue May 24 09:19:16 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198424, encodeId=ab521198424e3, content=攒积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=371e2458071, createdName=1240f287m62暂无昵称, createdTime=Tue Mar 01 17:41:32 CST 2022, time=2022-03-01, status=1, ipAttribution=)]
    2022-05-24 ms3000000261038156

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2116967, encodeId=9150211696e5f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bc408549151, createdName=ms8000001725758454, createdTime=Tue Feb 28 23:19:15 CST 2023, time=2023-02-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1222848, encodeId=313d1222848f9, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fab96394669, createdName=ms3000000753612435, createdTime=Fri May 27 18:48:56 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222055, encodeId=28da122205541, content=回复能给积分？, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220525/80a0ef79551841cbae693eaac50470ac/d51eaf2146ea41808ad01ccd5457204a.jpg, createdBy=c9596160557, createdName=ms6000001274998563, createdTime=Tue May 24 12:19:44 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221921, encodeId=e5d61221921f5, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f2d8154831, createdName=ms3000000261038156, createdTime=Tue May 24 09:19:16 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198424, encodeId=ab521198424e3, content=攒积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=371e2458071, createdName=1240f287m62暂无昵称, createdTime=Tue Mar 01 17:41:32 CST 2022, time=2022-03-01, status=1, ipAttribution=)]
    2022-03-01 1240f287m62暂无昵称

    攒积分

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

沙库巴曲缬沙坦钠共晶物药学特性专家共识

中国药学会医院药学专业委员会 · 2021-08-12

将姑息疗法整合到心力衰竭护理中：欧洲心脏病学会心力衰竭协会立场文件

欧洲心脏病学会(ESC,European Society of Cardiology) · 2021-11-02

欧洲心脏病学会/心力衰竭协会关于新型降糖药物在心力衰竭患者中的作用和安全性的立场文件

欧洲心脏病学会(ESC,European Society of Cardiology) · 2021-11-04

心力衰竭中的SGLT2抑制剂：超出血糖控制： 欧洲心脏病学会心力衰竭协会立场文件

欧洲心脏病学会(ESC,European Society of Cardiology) · 2021-11-02

心力衰竭患者的 COVID-19疫苗接种：欧洲心脏病学会心力衰竭协会的立场文件

欧洲心脏病学会(ESC,European Society of Cardiology) · 2021-10-01

中国心力衰竭诊断与治疗质量评价和控制指标专家共识

中国医师协会心血管内科医师分会心力衰竭学组 · 2021-03-20

拓展阅读

2010 中华医学会 急性心力衰竭诊断和治疗指南

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2010-01-01

心脏再同步治疗慢性心力衰竭的建议（2009年修订版）

中华医学会心电生理和起搏分会 · 2010-02-25

加拿大心衰诊疗指南（2010更新）：少数民族人口，心脏衰竭和怀孕，疾病管理，和质量改进/保证方案心力衰竭

加拿大心血管学会(CCS,Canadian Cardiovascular Society) · 2010-04-01

2010HFSA 心力衰竭治疗指南

美国心衰学会(HFSA,HEART FAILURE SOCIETY OF AMERICA) · 2010-07-01

2011AHA/ACC 急性心力衰竭综合征：急诊科表现、治疗、处置的现状及预期目的--来自美国心脏病协会科学声明

美国心脏协会(AHA,American Heart Association) · 2011-04-14

2012AHA 科学声明：心力衰竭诊疗进展科学决策

美国心脏协会(AHA,American Heart Association) · 2012-03-05